Search

Displaying results 2141 - 2150 of 10000 in total
  1. Drug

    Pravastatin

    go.drugbank.com/drugs/DB00175
    ApprovedInvestigational

    The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group.[T239] … Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin].[T303] Pravastatin was firstly approved in 1991 becoming the second available statin in the United States.

    Products: DAXON T
  2. Drug

    Acemetacin

    go.drugbank.com/drugs/DB13783
    ApprovedInvestigational

    Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and … it kept the same side effects.

    Products: RANTUDIL ® LP 90 MG CAPSULAS DE LIBERACIÓN PROLONGADA
  3. Drug

    Tavaborole

    go.drugbank.com/drugs/DB09041
    Approved

    Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes … Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).

  4. Drug

    Treprostinil

    go.drugbank.com/drugs/DB00374
    ApprovedInvestigational

    Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. … However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.

  5. Drug

    Moxisylyte

    go.drugbank.com/drugs/DB09205
    Approved

    [T45] According to the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired the denomination of orphan product by the FDA. … [L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s.

  6. Drug

    Oxaprozin

    go.drugbank.com/drugs/DB00991
    Approved

    Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.

  7. Drug

    Cryptenamine

    go.drugbank.com/drugs/DB00785
    Approved

    Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known. … It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.

  8. Drug

    Tolazamide

    go.drugbank.com/drugs/DB00839
    Approved

    A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

  9. Drug

    Cemiplimab

    go.drugbank.com/drugs/DB14707
    ApprovedInvestigational

    Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. … By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.

    Categories: Programmed Death Receptor-1 Blocking Antibody
  10. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    Tisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours. … The approval was based on tumour response and the durability of the response as demonstrated in InnovaTV 204 (NCT03438396): in this trial, the objective response rate was 24% and the median response duration

    Synonyms: HuMax-TF-ADC